Tuesday, August 18, 2026
ExploreSearch
Finance Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agent Rollout Outpaces Data Trust and Readiness
Enterprise adoption of agentic AI is accelerating fast — Siemens deepening its NVIDIA partnership for self-verifying agentic AI in chip design, Manulife expanding its Microsoft AI-governance partnership, and a wave of infrastructure launches (NVIDIA GPU-accelerated data processing, Dell exascale storage, new AI chip generations) — even as a new Google Cloud survey shows the underlying data foundation isn't ready: companies have AI access to only 45% of their data on average, data laggards see access fall to 30% or less, and only about half of organizations trust their AI agents' decisions. Meanwhile, insider selling at enterprise-AI bellwether C3.ai (CEO Thomas Siebel offloading $4.8M in shares) hints at investor caution layered under the adoption hype.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,812
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,812 facts checked against source5,219 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 25, 2026

Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength

View original at globenewswire.com
Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength BRISTOL, Tenn., March 25, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 2020 ASCO guidelines recommend no specific pharmacological intervention as standard of care for cancer anorexia cachexia

    60% confidence

  • There is no FDA-approved pharmacological treatment for cancer anorexia cachexia

    60% confidence

  • Following positive Phase 2 results and coverage by UK and USA media outlets, Artelo has received multiple expressions of potential collaboration interest from global and regional pharmaceutical companies

    60% confidence

  • The collaboration with Queen's University Belfast and partners broadens ART27.13's therapeutic profile beyond cancer-related anorexia while preserving internal focus on the lead indication

    60% confidence

  • ART12.11 showed antidepressant-like activity on par with sertraline with improved cognitive benefits in preclinical models

    60% confidence

  • ART26.12 showed sustained analgesic effects without development of tolerance in osteoarthritis pain model, matching naproxen in efficacy

    60% confidence

  • Artelo is not a one-trick biotech but a platform play in one of medicine's most underserved mechanistic categories

    60% confidence

  • ART27.13's 6.4% weight gain versus 5.4% weight loss in placebo represents a clinically meaningful signal in cancer anorexia cachexia

    60% confidence

Cited in these Via News reports